Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Kodiak Sciences Inc. logo

Kodiak Sciences Inc. (KOD) Stock Ticker

NASDAQ: KOD · Healthcare · Biotechnology
$89.92-2.62%
USD · as of 2026-09-29 · market cap $2.0B
Open KOD in TickrRead the KOD AI analysisDownload for iPhone

KOD right now

Up 138% in a month — 139 points ahead of its industry.
bullishBreaking out: New 52-week high with a golden cross
Tickr signals on KOD
Breaking outNew 52-week high with a golden cross
Options expect by Oct 6±27.6%
Options expect by Oct 29±57.1%
Priced in for Nov 12 earnings±69.1%
IV rank (30-day)99% · rich
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full KOD picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on KOD
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

KOD stock facts

Ticker symbolKOD
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$2.0B
CEOVictor Perlroth
Employees141
HeadquartersPalo Alto, CA, US
IPO date2018-10-04
Websitekodiak.com

What you can see for KOD on Tickr

Live KOD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the KOD report.

Rankings

Largest Healthcare companiesLargest companies by market cap

KOD peers

ANABBBOTEYPTNRIXOCSPHATPROKTNGX

FAQ

What is the ticker symbol for Kodiak Sciences Inc.?

The ticker symbol for Kodiak Sciences Inc. is KOD, listed on the NASDAQ Global Market.

What is KOD?

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials,…

HomeExploreMarketLists
All pages